News and Announcements
Appointment of Taiwan Distributor
- Published December 15, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
• Appointment of J&H Technology Co Ltd as Optiscan’s exclusive pre-clinical distributor for Taiwan
• J&H Technology is a distributor of leading United States and European pre-clinical equipment
Optiscan Imaging Limited (ASX: OIL) (‘the Company’ or ‘Optiscan’) announces that it has appointed J&H Technology as its exclusive distributor in Taiwan for the FIVE2(ViewnVivo) in the pre-clinical research market. This appointment follows the appointment of two (2) China distributors in Shanghai and Guangzhou in 2019 and a new distributor in North America in 2020. Taiwan represents an attractive market for the FIVE2 (ViewnVivo), being consistently ranked as the top knowledge economy in Asia, with its biomedical sector identified as one of the five pillar industries for its national development.
J&H Technology was founded in 2000 and has approximately 25 staff. It is a distributor for leading United States and European pre-clinical suppliers including ThermoFisher Scientific, PerkinElmer and Miltenyi Biotec.
Optiscan’s Executive Chairman Darren Lurie, said:
“The appointment of J&H Technology continues the expansion of our international distribution arrangements for the FIVE2 (ViewnVivo) in the pre-clinical research market. We are very pleased to have such a well-credentialled partner in an attractive market.”
About Optiscan Imaging Limited (ASX:OIL)
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
